Compare Amgen, Inc. (AMGN) vs Nebius Group NV (NBIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Nebius Group NV — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Nebius Group NV trades at $214 (market cap $55.77B). The key difference: Amgen, Inc. is far larger — about 3.5× Nebius Group NV's market cap, and Amgen, Inc. pays a 2.77% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| AMGN | NBIS | |
|---|---|---|
Market Cap | $196.12B | $55.77B |
Sector | Health | Technology |
52-Week High | $388.16 | $286.69 |
52-Week Low | $271.18 | $44.30 |
Enterprise Value | $241.41B | $55.97B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NBIS trades at $219.65, up 1.6% over the past day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $529.80 million in 2025 with a net income of $82.50 million, and analyst consensus is strongly bullish with an average price target of $248.00. Recent news highlights aggressive AI infrastructure expansion and partnerships, though volatility persists amid sector competition fears.
Outlook remains positive given strong analyst buy ratings and projected revenue growth to $878 million in 2026, but high valuation multiples and competitive threats from tech giants like Meta pose significant risks. Cash flow trends show heavy investing activity funded by financing, supporting growth but elevating leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
